Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in Eng… (NCT04637204) | Clinical Trial Compass
CompletedNot Applicable
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
United Kingdom1,540 participantsStarted 2020-11-24
Plain-language summary
The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with initial renal cancer diagnosis
* Patients diagnosed at Stage III or Stage IV (as defined in CAS): as evidence for advanced/metastatic RCC
* For patients with Stage I/II or patients with missing information on Staging
* Patients who received SACT1 treatment following initial renal cancer diagnosis through end of enrolment (31 July 2019)
* Patients who received cabozantinib or axitinib treatment
Exclusion Criteria:
* Diagnosis of concomitant tumour apart from non-melanoma skin cancer in the three years prior to the diagnosis of aRCC
* Less than 18 years of age at the time of initial aRCC diagnosis
* SACT treatment more than 30 days prior to initial aRCC diagnosis
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Duration of therapy for the index treatments of interest stratified by line of therapy (LoT)
Timeframe: From start of index treatment up to the end of treatment or start of subsequent therapy during data collection period (01 January 2011 and 31 January 2020)
2
Time between subsequent treatment lines
Timeframe: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
3
Sequencing of treatments (any treatments received from aRCC diagnosis until the end of follow up or death)
Timeframe: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)